

# ARCHIVIO ISTITUZIONALE DELLA RICERCA

# Alma Mater Studiorum Università di Bologna Archivio istituzionale della ricerca

Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

## Published Version:

Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma / Ricco, G; Cosma, C; Bedogni, G; Biasiolo, A; Guarino, M; Pontisso, P; Morisco, F; Oliveri, F; Cavallone, D; Bonino, F; Plebani, M; Brunetto, MR. - In: DISEASE MARKERS. SECTION A, CANCER BIOMARKERS. - ISSN 1574-0153. - ELETTRONICO. - 29:2(2020), pp. 189-196. [10.3233/CBM-190118]

This version is available at: https://hdl.handle.net/11585/959809 since: 2024-02-21

Published:

DOI: http://doi.org/10.3233/CBM-190118

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

(Article begins on next page)

This item was downloaded from IRIS Università di Bologna (https://cris.unibo.it/). When citing, please refer to the published version. This is the accepted manuscript of:

Ricco G, Cosma C, Bedogni G, Biasiolo A, Guarino M, Pontisso P, Morisco F, Oliveri F, Cavallone D, Bonino F, Plebani M, Brunetto MR.

Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma.

Cancer Biomark. 2020;29(2):189-196

The final published version is available online at: <u>https://doi.org/10.3233/cbm-190118</u>

## Rights / License:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<u>https://cris.unibo.it/</u>)

When citing, please refer to the published version.

#### Galley Proof

Cancer Biomarkers -1 (2020) 1–8 DOI 10.3233/CBM-190118 IOS Press

# Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma

Gabriele Ricco<sup>a,h</sup>, Chiara Cosma<sup>b</sup>, Giorgio Bedogni<sup>c</sup>, Alessandra Biasiolo<sup>d</sup>, Maria Guarino<sup>e</sup>, Patrizia Pontisso<sup>d</sup>, Filomena Morisco<sup>e</sup>, Filippo Oliveri<sup>a</sup>, Daniela Cavallone<sup>a</sup>, Feraccio Bonino<sup>c,f,g</sup>, Mario Plebani<sup>b</sup> and Maurizia Rossana Brunetto<sup>a,f,h,\*</sup>

<sup>a</sup>Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viewes, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of P. S., Pisa, Italy

<sup>b</sup>Department of Laboratory Medicine, University-Hospital of Padua, Padua, Italy

<sup>c</sup>Italian Liver Foundation (Fondazione Italiana Fegato, FIF), Basovizza, Tr. st., Italy

<sup>d</sup>Department of Medicine, University of Padua, Padua, Italy

<sup>e</sup>Gastroenterology Unit, Department of Clinical Medicine and Surgery University of Naples "Federico II", Naples, Italy

<sup>f</sup> Institute of Biostructure and Bioimaging, National Research Council, Naples, Italy

<sup>g</sup>University of Pittsburgh Medical Center Institute for Health. Chianciano Terme, Siena, Italy

<sup>h</sup>Internal Medicine, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

#### Abstract.

BACKGROUND: The time-related variability of HCC biomarkers has not been investigated so far.

**OBJECTIVE:** To assess the changes of alpha for protein (AFP) and protein induced by vitamin-K absence/antagonist-II (PIVKA-II) in patients with HCC (HCC+) as compared to patients without HCC (HCC-).

**METHODS:** AFP and PIVKA-II were measured by a single laboratory using an automated chemiluminescent-enzymeimmunoassay (Fujirebio Inc., Tokyo, <sup>1</sup>ap n) in 1163 sera of 418 cirrhotics (31.1% HBV, 58.6% HCV, 10.3% non-viral etiology) undergoing ultrasound HCC surve llar ce. The mean (range) number of effective time-points available for analysis was 2.8 (2.0 to 3.0); 124 patients with HCC v ere natched with 294 who remained HCC free for at least 12 months after the last specimen. AFP and PIVKA-II changes were estimated over time by means of a random-effect generalized least squares (RE-GLS) regression model under the missingness at random assumption.

**RESULTS:** Patients with and without HCC had comparable chronic liver disease etiology and staging. AFP/PIVKA-II median (25<sup>th</sup>; 75<sup>th</sup> percentile) values at the latest time-point were 4.2 (2.6; 8.6) ng/mL/32 (25; 42) mAU/mL in HCC- and 8.4 (4.4; 32.1) ng/mL/66 (32; 192) mAU/mL in HCC+ (p < 0.001). Log<sub>10</sub>AFP and log<sub>10</sub>PIVKA-II time-changes differed in HCC+ and HCC- patients. In HCC+ patients, both log<sub>10</sub>AFP and log<sub>10</sub>PIVKA-II showed an increasing trend over time. In HCC- patients, log<sub>10</sub>PIVKA-II variations were minimal as compared to log<sub>10</sub>AFP variations. The percent increase of log<sub>10</sub>AFP at 6 months vs. baseline was 11% (95%CI 5 to 17%) and 5% (95%CI 1 to 8%) for log<sub>10</sub>PIVKA-II in HCC+ vs. HCC- patients.

**CONCLUSIONS:** The present retrospective study of the biological variability of AFP and PIVKA-II suggests that their timerelated changes may serve as potential predictors of HCC. This topic needs to be addressed by longitudinal studies.

Keywords: AFP, biomarkers, cirrhosis, hepatocellular carcinoma, PIVKA-II, surveillance

\*Corresponding author: Maurizia Rossana Brunetto, Hepatology<br/>Unit and Laboratory of Molecular Genetics and Pathology of Hep-<br/>atitis Viruses, Reference Center of the Tuscany Region for ChronicLiver Disease and Cancer, University Hospital of Pisa, Via Paradisa<br/>2, Pisa, 56124, Italy. Tel.: +39 50 99 68 57; Fax: +39 50 99 54 57;<br/>E-mail: maurizia.brunetto@unipi.it.

2

1

G. Ricco et al. / Modeling the time-related fluctuations of AFP and PIVKA-II serum levels

#### 1. Introduction

Hepatocellular carcinoma (HCC) has a worldwide 2 incidence ranging from 5 to 20 per 100,000 individuals 3 and is the 5<sup>th</sup> most common cancer in men and the 9<sup>th</sup> in 4 women [1-3]. The incidence rate > 1.5% per year in at-5 risk populations such as cirrhotic patients recommends 6 performing surveillance and several evidences suggest 7 that early diagnosis improves HCC management [4]. 8 HCC surveillance is mainly based on ultrasound 9 scan (US) whose effectiveness is highly operator-10 dependent [4–7]. Alpha-fetoprotein (AFP) and protein 11 induced by vitamin-K absence/antagonist-II (PIVKA-12 II) are the best available circulating biomarkers for the 13 diagnosis of HCC [8–11]. However, they have some 14 limitations as diagnostic tools for HCC because the eti-15 ology and the activity of the undergoing liver disease af-16 fect their diagnostic performance [12,13]. To date there 17 is no agreement among international guidelines about 18 the use of biomarkers in HCC surveillance; they are 19 not recommended by the European Association for the 20 Study of the Liver (EASL) [6], while AFP testing every 21 six months can be performed together with periodic US 22 according to the American Association for the Study of 23 Liver Disease (AASLD) [4]. 24

AFP serum levels are influenced by liver regenera-25 tion following necrosis and inflammation [14] and fluc 26 tuate differently in patients with active liver disease ind 27 in those responding to antiviral therapy. PIVLA-II is 28 an immature form of prothrombin whose setur levels 29 increase in the presence of HCC following a defect in a 30 post-translational vitamin-K-depend .n. carboxylation 31 of ten glutamic acid residues at the anti-o-terminal [15]. 32 Although PIVKA-II shows a higher specificity to HCC 33 (> 80%), the presence of factor affecting the cycle of 34 vitamin-K, such as drugs of impaired absorption, can 35 lead to non-specific elevations [16]. 36

As a consequence, the fluctuations of these biomark-37 ers in several pathophysiological non-malignant con-38 ditions can be relevant and the identification of spe-39 cific univocal cut-offs to detect HCC might be subop-40 timal because of their biological variability. More re-41 cently, some studies have shown that the analysis of 42 single-point continuous values of HCC biomarkers by 43 means of statistical models could improve the diag-44 nostic accuracy rather than the application of specific 45 cut-offs [17,18]. However, the use of serial measures of 46 biomarkers might improve their performance for HCC 47 screening since multiple testing would allow to compute 48 their kinetics and the magnitude and rate of their change 49 over time. Both the kinetics and the rate of change of 50

the biomarkers' serum levels over time (velocity) might have advantages over a single measurement in differentiating patients with cirrhosis and benign regeneration nodules from patients with nodules progressing to HCC.

The aim of the present case-control study was to assess the time-related variations of serum AFP and PIVKA-II levels in cirrhotic patients who did or did not develop HCC during surveillance.

#### 2. Patients and methods

#### 2.1. Study design

We performed a retrospective repeated-measure casecontrol study on cirrhetic patients undergoing surveillance for HCC. Cases were patients with HCC development and controls were patients who had not devel-65 oped HCC for 22 least 12 months from the last available serum sample. We enrolled 418 consecutive cirrhotic p. tients with chronic liver disease (CLD) of difference iology undergoing HCC surveillance in three 69 It dia n Hepatology centers [200 (47.8%) in Pisa, 162 (32.5%) in Naples, 56 (13.4%) in Padua] for whom at 71 least two serum samples were available. In 124 patients 72 with HCC development (HCC+) one serum specimen 73 was obtained at the time of HCC diagnosis and one 74 or two serum specimens were available before HCC diagnosis. Two or three serum specimens were available also from the remaining 294 patients who did not developed HCC for at least 12 months after the collection of the last serum (HCC-). Liver cirrhosis was diagnosed at histology or based on unequivocal ultrasound/transient elastography/endoscopic features (liver morphology suggestive of cirrhosis, esophageal varices and/or other signs of portal hypertension) and/or clini-83 cal history of liver decompensation (ascites and/or hep-84 atic encephalopathy). HCC was diagnosed on the basis of a typical vascular pattern of focal liver lesions obtained at imaging [computed tomography (CT), magnetic resonance imaging (MRI), contrast-enhanced ultrasound imaging (CEUS)], according to the EASL current guidelines for HCC [6]. The study was approved by the local Ethical Committee and conforms with The Code of Ethics of the World Medical Association (Declaration of Helsinki). All patients gave their written 93 informed consent.

#### 2.2. Laboratory assessment

Sera were stored at  $-20^{\circ}$ C until they were tested for

95

96

51

52

53

54

55

56

57

58

59

60

61

62

63

64

66

67

68

70

75

76

77

78

79

80

81

82

85

86

87

88

89

90

91

92

G. Ricco et al. / Modeling the time-related fluctuations of AFP and PIVKA-II serum levels

AFP and PIVKA-II by means of two quantitative fully 97 automated chemiluminescent-enzyme-immunoassays 98 (CLEIA) on Lumipulse G1200 (Fujirebio Inc., Tokyo, 99 Japan). The analytical sensitivity of the method was 100 0.8 ng/mL for the AFP assay (dynamic range 0.8 to 101 22451 ng/mL and upper normal limit 7.4 ng/mL) and 102 1.37 mAU/mL for the PIVKA-II assay (dynamic range 103 1.37 to 75000 and upper normal limit 48 mAU/mL). 104 The coefficient of variation (CV) is < 3.3% for AFP 105 and < 4.0% for PIVKA-II measurement [19]. All tests 106 were performed in a single run at the reference lab-107 oratory of the University Hospital of Padua. Samples 108 with results exceeding the dynamic range values were 109 retested following appropriate dilution. 110

#### 2.3. Statistical analysis 111

Most continuous variables were not Gaussian-112 distributed and reported as median (25<sup>th</sup>; 75<sup>th</sup> per-113 centile). Categorical variables are reported as num-114 bers and proportions. Differences between HCC+ 115 and HCC- were analyzed using median regression 116 and Pearson's Chi-square test for continuous and 117 categorical variables, respectively. The time-related 118 changes of AFP and PIVKA-II in cases (HCC+) and 119 controls (HCC-) were retrospectively estimated us-120 ing a random-effect generalized least squares (RE-121 GLS) regression model [20]. The response variable of 122 the RE-GLS model were  $\log_{10}$ -transformed APP or 123 log<sub>10</sub>-transformed PIVKA-II. The log-transfor nation 124 was used to reduce the expected skewness of the re-125 sponse variable. The pre-specified predictors of the RE-126 GLS model were time (continuous, years), squared time 127 (continuous), HCC (dichotomous, 0 = no; 1 = yes), 128 an HCC\*time (dichotomous\*continuous) interaction, 129 and an HCC\*squared time (dichotomous\*continuous) 130 interaction. The RE-GLS riodel was pre-specified be-131 cause this is the best strategy to test a study hypothesis 132 via regression analysis [20]. In particular, we did not 133 explore other transformations of time besides squared 134 time because of the availability of just three time-points 135 and of the varying distance between them. Coherently 136 with the pre-specified nature of the model, predictors 137 were kept into it independently of their statistical sig-138 nificance [20]. It should be noted that, in the presence 139 of significant interactions, the main effects cannot be 140 interpreted as such and estimates made by the regres-141 sion model have to be used [20]. We plotted these esti-142 mates to aid the clinical interpretation of the findings. 143 The random effect of the RE-GLS was assigned to the 144 patient. Internal cross-validation was performed using 145

Table 1   Main characteristics of HCC+ cases				
		n (%) or media (25 <sup>th</sup> ; 75 <sup>th</sup> percentile)		
Sex	F	21 (16.9)		
	М	103 (83.1)		
Age at diagnosis	Years	65.9 (59.5; 72.7		
Center	Pisa	93 (75.0)		
	Naples	23 (18.5)		
	Padua	8 (6.5)		
Etiology	HBV	37 (29.8)		
	HCV	75 (60.5)		
	Non-viral	12 (9.7)		
Child-pugh score		5 (5; 5)		
Child-pugh class	А	115 (92.7)		
	В	9 (7.3)		
Description HCC	Single no dule	102 (82.3)		
1	2-3 noa les	17 (13.7)		
	> 3 nou ile/diffuse	5 (4.0)		
Max diameter lesion	m.r	21 (8; 120)		
BCLC stage	C	50 (40.3)		
	in a start and a start	51 (41.1)		
0	В	2 (1.6)		
	С	12 (9.7)		
	D	9 (7.3)		

Notes: BCLC: Barcelona Clinic Liver Cancer.

bootstrap on 1000 samples with replacement. This is 146 expected to correct for over-optimism and make the model more generalizable [20]. We also run the RE-GLS model using the study center as cluster (0 = Pisa; 1 =Naples; 2 =Padua), i.e. by bootstrapping the patients with replacement within each center [20] but this did not change the findings and is not reported here. The RE-GLS is robust to missing data provided that they are missing at random, which is a reasonable assumption for the present study. The mean (range) number of 155 effective time-points available for analysis was 2.8 (2.0 156 to 3.0) for both  $log_{10}AFP$  and  $log_{10}PIVKA-II$ . Boot-157 strapped 95% confidence intervals (95% CIs) are re-158 ported for the regression coefficients and the estimates 159 obtained from the RE-GLS model [20]. Statistical anal-160 ysis was performed using Stata 15.1 (Stata Corporation, 161 College Station, TX, USA). 162

#### 3. Results

#### 3.1. Patients characteristics

Four hundred and eighteen patients were selected for the present study: 124 HCC+ cases and 294 HCCcontrols. The main characteristics of HCC+ cases are reported in Table 1. The majority of HCC were di-168 agnosed at a very early or early stage [BCLC 0 in 169

163

164

165

166

167

Λ
=

G. Ricco et al. / Modeling the time-related fluctuations of AFP and PIVKA-II serum levels

		Tabl Demographic and			
		HCC - (n = 294)	HCC+(n = 124)	Overall $(n = 418)$	p value
Sex	F	77 (26.2)	21 (16.9)	98 (23.4)	0.05
	Μ	217 (73.8)	103 (83.1)	320 (76.6)	
Etiology	HBV	93 (31.6)	37 (29.8)	130 (31.1)	0.880
	HCV	170 (57.8)	75 (60.5)	245 (58.6)	
	Non-viral	31 (10.5)	12 (9.7)	43 (10.3)	
Center	Pisa	107 (36.4)	93 (75.0)	200 (47.8)	< 0.00
	Naples	139 (47.3)	23 (18.5)	162 (38.8)	
	Padua	48 (16.3)	8 (6.5)	56 (13.4)	
Age	(Years)	63.5 (56.5; 69.7)	65.9 (59.5; 72.7)	64.2 (56.7; 70.8)	0.019
AFP	(ng/mL)	4.2 (2.6; 8.6)	8.4 (4.4; 32.1)	5.0 (3.0; 10.2)	< 0.00
PIVKA-II	(mAU/mL)	32 (25; 42)	66 (32; 192)	35 (26; 61)	< 0.00
AST	(U/L)	26 (22; 36)	43 (25; 78)	29 (22; 46)	< 0.00
ALT	(U/L)	22 (17; 33)	34 (22; 83)	26 (18; 47.2)	< 0.00
GGT	(U/L)	31 (19; 57)	60 (33; 105)	38 (22; 74.7)	< 0.00
ALP	(U/L)	77 (62; 98)	103 (82; 133)	85 (65; 115.5)	< 0.00
Albumin	(g/dL)	4.3 (4.0; 4.5)	4.1 (3.8; 4.4)	4.2 (3.9; 4.5)	0.03
PT	(%)	82 (60; 97)	83 (73; 93)	82 (68.2; )4)	0.43
INR		1.10 (1.02; 1.24)	1.11 (1.06; 1.21)	1.10 (1.03; 1.21)	0.53
Total bilirubin	(mg/dL)	0.96 (0.60; 1.48)	0.79 (0.59; 1.20)	0.9( 09; 1.37)	0.19
PLTs	$(\times 10^{9}/L)$	120 (89; 165)	111 (77; 155)	1.4 (82; 157)	0.19
Child-pugh score		5 (5; 5)	5 (5; 5)	5 (5; 5)	0.67
Child-pugh class	А	272 (92.5)	115 (92.7)	267 (92.6)	0.940
	В	22 (7.5)	9 (7.3)	31 (7.4)	

Notes: AFP, alpha-fetoprotein; ALP, alkaline phosphatase; ALT, alapine uninotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; INR, International 1 orm lized ratio; PIVKA-II, Protein induced by Vitamin K Absence/Antagonist-II; PT, Prothrombin time; PLT, p. tetets. Laboratory data refer to the last serum specimen collected. Continuous variables are reported as me fia. (25<sup>th</sup>, 75<sup>th</sup> percentile).

50 (40.3%), BCLC A in 51 (41.1%)]. Demographic 170 and laboratory data are reported in Table 2 stratified 171 by HCC status. Continuous variables are expressed 172 as median (25th; 75th percentile) and refer to the last 173 serum specimen collected, which is the nearest to the 174 diagnosis in patients who developed HCC. HCC+ pa-175 tients were 93/200 (46.5%) in Pisa, 23/162 (14.2%) in 176 Naples and 8/56 (14.3%) in Padaa. Men were more 177 common than women both among HCC+ (103/124, 178 83.1%) and HCC- patients (217/294, 73.8%). The eti-179 ology of chronic liver disease was HBV in 37 (29.8%) 180 of HCC+ and 93 (31.6%) of HCC- patients; HCV in 181 75 (60.5%) of HCC+ and 170 (57.8%) of HCC- pa-182 tients; non-viral in 12 (9.7%) of HCC+ and 31 (10.5%) 183 of HCC- patients. 184

AFP and PIVKA-II serum levels were higher in HCC+ than HCC- (p < 0.001). HCC+ patients showed higher levels of liver enzymes and albumin. Nevertheless, the majority of patients showed a preserved liver function (Child-Pugh A in 92.6%), without differences between groups (92.5% in HCC- and 92.7% in HCC+).

192 *3.2. Modeling analysis* 

A total of 1163 serum samples were evaluated. Two serum samples were available for 91 patients (29 HCC+ and 62 HCC–) and three for 327 patients (95 HCC+ and 232 HCC–). The median (minimum; maximum) time elapsed between the first and the last serum collection was 13.1 (3.2; 96.0) in HCC+ and 22.8 (2.0; 74.5) months in HCC– patients.

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209


The median (minimum; maximum) time at which the last serum specimen was collected in the 124 HCC+ patients was 0.1 (-3.6; 4.7) months within the diagnosis of HCC. The 297 HCC- patients remained free from HCC for a median (minimum; maximum) time of 14.2 (12.1; 71.7) months after the last serum specimen.

The distribution of the two biomarkers in HCC+ and HCC- is given in Fig. 1. Overall, median values (25<sup>th</sup>; 75<sup>th</sup> percentile) of AFP and PIVKA-II were 5.6 (3.1; 11.8) ng/mL and 34 (26; 51) mAU/mL, respectively.

The time-related changes of log<sub>10</sub>AFP and 210 log<sub>10</sub>PIVKA-II as estimated by the RE-GLS model are 211 plotted in Fig. 2. Both log<sub>10</sub>AFP and log<sub>10</sub>PIVKA-II 212 differ in HCC+ vs. HCC- patients at all time-points 213 except at 48 months where the precision of the model 214 decreases due to a greater dispersion of data points. An 215 identical pattern is obtained by modeling male and fe-216 male data separately (not shown). The regression coef-217 ficients for the fixed part of the RE-GLS model used to 218 investigate the changes of log<sub>10</sub>AFP and log<sub>10</sub>PIVKA-219 II in HCC+ vs. HCC- patients are reported in Table 3. 220

2/07/2020; 14:48

Galley Proof







Fig. 2. Changes in  $log_{10}AFP$  and  $log_{10}PIVKA$ -II as estimated by the RE-GLS model in HCC+ (red line) and HCC- (green line). Values are means and 95% bootstrapped confidence intervals (see statistical analysis for details). Between-group differences are obtained by subtracting HCC+ minus HCC-.

6



G. Ricco et al. / Modeling the time-related fluctuations of AFP and PIVKA-II serum levels

Fig. 3. Ratios between the value of  $\log_{10}$ AFP and  $\log_{10}$ PIVKA-II at selected time-points (3, 6, 12, 24, 36 and 48 months) vs. the baseline as estimated from the RE-GLS model by means of non-linear contrasts in and HCC- (panel a) and HCC+ (panel b) patients (see statistical analysis for details). Values higher or lower than 1 indicate increasing or decreasing trends respectively. Shaded areas are 95% CI confidence intervals.

227

Figure 3 shows the ratios between a given time-point (3, 6, 12, 24, 36 and 48 months) and the baseline of  $log_{10}AFP$  and  $log_{10}PIVKA$ -II in HCC+ and HCCpatients as estimated from the RE-GLS model by means of non-linear contrasts. In HCC– patients, log<sub>10</sub>AFP 225 and log<sub>10</sub>PIVKA-II show different time-courses, with 226 the latter being highly stable over time and showing

lower 95% CIs compared to log<sub>10</sub>AFP (panel a). In 228 HCC+ patients, the ratios become increasingly greater 229 than 1 with time (panel b). The precision of the esti-230 mate as conveyed by 95% CI is higher for PIVKA-II and greatly decreases for both markers after 24 months because of the lower number of available time-points. To further characterize the variability of AFP and

G. Ricco et al. / Modeling the time-related fluctuations of AFP and PIVKA-II serum levels

Table 4			
nge vs. baseline at given ti	me-points in HCC+ versu		
0	1		
$I_{OGI} \circ \Lambda FP(\mathcal{O}_{O})$	Log10PIVKA-II (%)		
$Log_{10}AH$ ( $\mathcal{M}$ )	Log1011 V KA-II (70)		
6 (3 to 9) p < 0.001	2 (0  to  4) p = 0.017		
11 (5 to 17) $p < 0.001$	5 (1  to  8) p = 0.012		
19 (10 to 29) $p < 0.001$	8 (3 to 14) $p = 0.005$		
27 (15 to 38) $p < 0.001$	14 (6 to 21) $p < 0.001$		
23 (6 to 39) $p = 0.009$	16 (5 to 26) $p = 0.003$		
7(-29  to  42) p = 0.717	15 (-6  to  36) p = 0.163		
	nge vs. baseline at given the ents $Log_{10}AFP (\%)$ $\hline 6 (3 to 9) p < 0.001$ $11 (5 to 17) p < 0.001$ $19 (10 to 29) p < 0.001$ $27 (15 to 38) p < 0.001$ $23 (6 to 39) p = 0.009$		

95% bootstrapped confidence intervals in brackets.

PIVKA-II, we computed the percent change estimated 235 from the RE-GLS model using non-linear contrasts at a 236 given time-point (3, 6, 12, 24, 36 and 48 months) versus 237 the baseline value in HCC+ compared to HCC- pa-238 tients (Table 4). The analysis shows that the percentage 239 variability of  $log_{10}AFP$  is higher than the variability of 240 log<sub>10</sub>PIVKA-II. The width of 95% CIs indicates that the 241 accuracy of the estimate is higher for log<sub>10</sub>PIVKA-II 242 than log<sub>10</sub>AFP. 243

### 244 **4. Discussion**

The time-changes of any biomarker are the result of 245 both the analytical and biological variability. When the 246 analytical imprecision of the assay is sufficiently low, 247 the biological variation retains a potential clinical value 248 that needs to be addressed. In particular, when Jealing 249 with biomarkers for cancer surveillance, it would be 250 crucial to discriminate the extent of variability that is 251 the expression of non-malignant conditions from a vari-252 ability that is likely to indicate an ongoing neoplastic 253 process. 254

In the present case-control study, we aimed to esti-255 mate the time-changes of AFP and PIVKA-II in patients 256 with and without HCC Jevelopment. Interestingly, in 257 HCC+ patients both AFP and PIVKA-II were esti-258 mated to increase over time, confirming their potential 259 usefulness during periodic surveillance. On the other 260 hand, among HCC– patients the time-related changes 261 of PIVKA-II were more stable than those of AFP. The 262 different trajectories of PIVKA-II in HCC+ and HCCpatients are likely to reflect the mechanism of PIVKA-264 II production, which, contrarily to AFP, is not affected 265 by liver disease activity [21]. 266

The design of the present retrospective study was not intended to quantify the extent of the clinically relevant variability for HCC diagnosis. We computed, however, the percent time-related changes of  $log_{10}AFP$ and  $log_{10}PIVKA-II$  in HCC+ vs. HCC- patients using a RE-GLS regression model. At 6 months, i.e. the first 272 reference time-point for US surveillance of patients 273 at risk of HCC development, we found a 11% (95%) 274 CI 5 to 17%) increase of  $\log_{10}$ AFP and a 5% (95%) 275 CI 1 to 8%) increase of log<sub>10</sub>PIVKA-II compared to 276 baseline in HCC+ vs. HCC- patients. The 95% CIs of 277  $log_{10}$ PIVKA-II were narrower than those of  $log_{10}$ AFP 278 (not only at 6 months but at any time-point). According 279 to these data, any increase of serum PIVKA-II levels 280 above 2 standard deviations of the analytical variability 281 of the assay is likely to be clinically relevant for the 282 diagnosis of HCC while AFP changes are expected to 283 be much more variable. 284

These findings are consistent with the notion that 285 disease activity affects the magnostic performance of 286 AFP more than that of YN KA-II [22]. Accordingly, 287 disease activity was highly variable in our population; 288 ninety percent of our patients with HBV-related CLD 289 were in fact undergoing antiviral treatment with nu-290 cleos(t)ide an item and had a suppressed viremia and 291 normal liver chzymes. On the contrary, only 31% of 292 our patients with HCV-related CLD were undergoing 293 antiv ral treatment and 43% of them had normal liver 294 ci zyi hes. Since a prolonged remission of disease limits 295 the confounding effect of necro-inflammation on AFP 296 serum levels, future analyses are needed to reconsider 297 AFP diagnostic performance in patients with sustained 298 virologic response. 299

The present study has several limitations. The major 300 limitation is the fact that the time-points which were 301 used to model the time-course of AFP and PIVKA-II 302 were not equally spaced. To account for this fact, we 303 used a RE-GLS with a pre-specified shape for time 304 and the time\*HCC interaction and a random effect at 305 the patient-level (see statistical analysis for details). 306 Although this is acceptable on theoretical grounds, it 307 would be much better to analyze equally spaced time-308 points (e.g. 6, 12 and 24 months) because a program of 309 HCC surveillance is usually based on such fixed time 310 frame. Another limitation is the aforementioned hetero-311 geneity of the study patients, who had liver cirrhosis 312 of different etiology and different disease activity. On 313 the other hand, such population is ideal for performing 314 a general proof-of-concept study of the variability of 315 HCC markers, as we did here, because it offers a dif-316 ferent case-mix of patients. Another limitation is that 317 HCC frequency differed substantially among the three 318 study centers, being 46.5% in Pisa, 14.2% in Naples 319 and 14.3% in Padua. There was certainly a selection 320 bias due to the inclusion criterion specifying that at least 321 two repeated sera per patient were needed for inclusion 322

\_7

8

362

363

364

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

#### G. Ricco et al. / Modeling the time-related fluctuations of AFP and PIVKA-II serum levels

#### into the present analysis. However, bootstrapping the 323

**RE-GLS** model with replacement within each center 324 did not change our findings (data not shown). 325

In conclusion, we found that time-changes of 326 PIVKA-II and AFP have the potential for being em-327 ployed as early markers of HCC. The evidence pro-328 vided by this proof-of-concept study suggests perform-329 ing prospective studies of the time-course of AFP and 330 PIVKA-II to identify their specific time-related varia-331

tions to be used as early marker of HCC. 332

#### References 333

334

335

336

337

338

339

341

342

343

344

345

346

347

350

351

352

353

354

355

356

357 358

359

360

- F.X. Bosch et al., Primary liver cancer worldwide incidence [1] and trends, Gastroenterology 127(5 Suppl 1) (2004), S5-S16.
- [2] H.B. El-Serag, Epidemiology of viral hepatitis and hepatocellular carcinoma, Gastroenterology 142(6) (2012), 1264-1273.
- H.B. El-Serag, Surveillance for hepatocellular carcinoma: in [3] whom and how? Therap Adv Gastroenterol 4(1) (2011), 5-10.
- J.K. Heimbach et al., AASLD guidelines for the treatment of [4] 340 hepatocellular carcinoma, Hepatology 67(1) (2018), 358-380.
  - [5] A. Singal et al., Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 30 (2009), 30-47.
  - [6] European Association for the Study of Liver, EASL clinical practice guidelines: management of hepatocellular carcinoma, J Hepatol 69(1) (2018), 182-236.
- M. Kudo et al., JSH consensus-based clinical practice guide-[7] 348 lines for the management of hepatocellular carcinoma: 2011 349 update by the liver cancer study group of japan, Liver Can. er 3(3-4) (2014), 458-468.
  - A.S. Lok et al., Des-gamma-carboxy prothrombin and alpha-[8] fetoprotein as biomarkers for the early detection of hepatocellular carcinoma, Gastroenterology 138 (2010), 193-502.
  - C. Li et al., Diagnostic accuracy of des-gran. a- arboxy pro-[9] thrombin versus alpha-fetoprotein for net atocellular carcinoma: a systematic review, Hepatol Re. 4 (10) (2014), 11-25.
  - [10] E.S. Jang et al., Diagnostic performance of alpha-fetoprotein, protein induced by vitamin K ab enc), osteopontin, dickkopf-1 and its combinations for herate cenular carcinoma, PLoS One 11(3) (2016), e0151069.4

- [11] T.S. Lim et al., Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients, Scand J Gastroenterol 51(3) (2016), 344-353. 365
- [12] T.I. Huo et al., The predictive ability of serum alpha-fetoprotein for hepatocellular carcinoma is linked with the characteristics of the target population at surveillance, Journal of Surgical Oncology 95 (2007), 645-651.
- [13] G. Ricco et al., Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers, Cancer Biomark 21(3) (2018), 603-612.
- [14] P. Gopal et al., Factors that affect accuracy of a-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis, Clin Gastroenterol Hepatol 12(5) (2014), 870-877.
- H.A. Liebman et al., Des-gamma-carboxy (abnormal) pro-[15] thrombin as a serum marker of primary hepatocellular carcinoma, N Engl J Med 310 (1984), 1427-1431.
- [16] H. Xing et al., Clinical application of protein induced by vitamin K antagonist-II as a com. rker in hepatocellular carcinoma, Tumour Biol 37 (2015), 15447-15456.
- [17] P.J. Johnson et al., The acted tion of hepatocellular carcinoma using a prospectiv iv ivveloped and validated model based on serological bio barkers, Cancer Epidemiol Biomarkers Prev 23(1) (2014), 14-153.[18] P.M. Hen, c. et al., Validation of a novel model for the early
- detection hepatocellular carcinoma, Clin Proteomics 16(2) (20.9), 1-9.
- Choi et al., Evaluation of automated serum des-[19] 5. an macarboxyprothrombin (DCP) assays for detecting hepaocellular carcinoma, Clin Biochem 44(17-18) (2011), 1464-1468
- [20] F.E. Harrell, Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis. Springer, Switzerland, 2015.
- [21] K. Murata et al., Cytoskeletal changes during epithelialto-fibroblastoid conversion as a crucial mechanism of desgamma-carboxy prothrombin production in hepatocellular carcinoma, Int J Oncol 35(5) (2009), 1005-1014.
- [22] G.A. Kim et al., Reappraisal of serum alpha-foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment, Liver Int 35(1) (2015), 232-239.